TopNewsOn
Business

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Sonja Wind·Bloomberg·November 4, 2026

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

Read the full story at Bloomberg →